Drugs / APL-9
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04402060 | May 2020 → Feb 2021 | COVID-19, acute respiratory distress syndrome, severe acute respiratory syndrome | Apellis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04402060 ↗ |
| Action | Inhibit | “APL-9 has been designed to inhibit or block activation of part of the complement pathway” NCT04402060 ↗ |
| Route | Intravenous | “180 mg APL-9 IV plus SOC” NCT04402060 ↗ |